HLAVNÍ TÉMA Dyslipidemie u kardio-reno-metabolického syndromu | 387 / Vnitř Lék. 2026;72(6):382-387 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 22. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9:653-662. 23. Nicholls SJ, Pavo I, Bhatt DL, et al.; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025; 393:24092420. 24. Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2 b Study. Diabetes Care 2021; 44:1433-1442. 25. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023; 14:8289. 26. Briand F, Augustin R, Wesche F, et al. Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model. Diabetes 2024; 73 (Supplement_1): 1635–P. 27. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active- -controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402:529-544. 28. Jastreboff AM, Kaplan LM, Frías JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023; 389:514-526. 29. Mach F, Koskinas KC, Roeters van Lennep JE, et al.; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46:4359-4378. 30. Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397-1405. 31. Cholesterol Treatment Trialists’ (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125. 32. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372:2387-2397. 33. Giugliano RP, Cannon CP, Blazing MA, et al.; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137:1571-1582. 34. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192. 35. Singh A, Kesani H, Verma S, et al. Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management. Cureus 2025; 17:e94134. 36. Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab 2019; 21:903-908. 37. Imbalzano E, Ilardi F, Orlando L, et al. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2023; 9:318-327. 38. Igweonu-Nwakile EO, Ali S, Paul S, et al. A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. Cureus 2022;14:e29140. 39. Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab 2024; 26:3223-3237. 40. Landmesser U, Ray KK, Raal FJ, et al.; ORION Investigators. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials. J Am Soc Nephrol 2026; doi: 10.1681/ ASN.0000001006. 41. Cao YX, Liu HH, Dong QT, et al. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20:1391-1398. 42. Li F, Ye H, Chen L, et al. Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin. Front Pharmacol 2025; 16:1554631. 43. Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388:1353-1364. 44. Leiter LA, Banach M, Catapano AL, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 2022; 24:868-880. 45. Ray KK, Bloedon L, Li N, Nissen SE; co-authors. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors’ reply. Lancet Diabetes Endocrinol. 2024; 12:228-229. 46. Stemmer K, Finan B, DiMarchi RD, et al. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Adv Drug Deliv Rev 2020; 159:34-53. 47. O’Brien RC, Abdallah K, Dong X, et al. Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. J Diabetes 2026; 18:e70193. 48. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628. Praha 12. května 2027 2. kongres diabetologie pro praxi www.diabetologiepraha.cz
RkJQdWJsaXNoZXIy NDA4Mjc=